RED 152005

Drug Profile

RED 152005

Latest Information Update: 17 Apr 2007

Price : $50

At a glance

  • Originator XiMed Group
  • Class Antiparasitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pediculosis

Most Recent Events

  • 17 Apr 2006 Discontinued - Phase-I for Pediculosis in United Kingdom (Topical)
  • 17 Nov 2003 Ximed Group is now called Eden Research
  • 08 Jan 2001 Phase-I clinical trials for Pediculosis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top